key: cord-0787555-gctyy00l authors: Li, Tong‐Zeng; Cao, Zhen‐Huan; Chen, Yu; Cai, Miao‐Tian; Zhang, Long‐Yu; Xu, Hui; Zhang, Jia‐Ying; Ma, Chun‐Hua; Liu, Yang; Gao, Li‐Juan; Duan, Zhong‐Hui; Mou, Dan‐Lei; Liang, Lian‐Chun title: Duration of SARS‐CoV‐2 RNA shedding and factors associated with prolonged viral shedding in patients with COVID‐19 date: 2020-07-09 journal: J Med Virol DOI: 10.1002/jmv.26280 sha: 690d1b0b0b669d81b7f5d4e3383737886e525ea9 doc_id: 787555 cord_uid: gctyy00l AIM: To investigate the factors associated with the duration of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) RNA shedding in patients with coronavirus disease 2019 (COVID‐19). METHODS: A retrospective cohort of COVID‐19 patients admitted to a designated hospital in Beijing was analyzed to study the factors affecting the duration of viral shedding. RESULTS: The median duration of viral shedding was 11 days (IQR, 8‐14.3 days) as measured from illness onset. Univariate regression analysis showed that disease severity, corticosteroid therapy, fever (temperature>38.5℃), and time from onset to hospitalization were associated with prolonged duration of viral shedding (p<0.05). Multivariate regression analysis showed that fever (temperature>38.5℃) (OR 5.1, 95%CI: 1.5‐18.1), corticosteroid therapy (OR 6.3, 95%CI: 1.5‐27.8), and time from onset to hospitalization (OR 1.8, 95%CI: 1.19‐2.7) were associated with increased odds of prolonged duration of viral shedding. CONCLUSIONS: Corticosteroid treatment, fever (temperature>38.5℃), and longer time from onset to hospitalization were associated with prolonged viral shedding in COVID‐19 patients. This article is protected by copyright. All rights reserved. shedding were also excluded. To ensure the accuracy of the time of onset, patients under 18 years old (n=6) and patients whose time from onset to hospitalization was more than 7 days (n=17) were excluded. The remaining 66 patients were included in the data analysis (Fig 1) . The median age of these 66 patients was 47.5 years (IQR, 36-63.5 years) and 39.4% of the enrolled patients were female (Table 1 ). The median DVS was 11 days (IQR, 8-14. 3 days), and the DVS in 35 patients was more than 11 days. The median age of the patients in the short DVS group was 46 years, which was significantly lower than that in the long DVS group (59 years, p=0.042); 25.7% of patients in the short DVS group had a fever, while 61.3% of patients in the long DVS group had a fever, the difference between the two groups was statistically significant (p=0.004). The number of general, severe, and critical cases in the short DVS group was 30, 4, and 1, respectively, and was 16, 7, and 8, respectively, in long DVS group (p=0.004) ( Table 1 ). The DVS in the general, severe and critical patient groups was 9.5 days (IQR, 8-13), 12 days (IQR, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , and 17 days (IQR, 13.5-18.5), respectively, with significant differences between the groups (p=0.004). The time from onset to hospitalization in the short DVS group was shorter than that in the long DVS group (4 versus 5 days, p=0.008). The median time from illness onset to discharge was 13.0 days (IQR, 10.0-16.0) in the short DVS group, and was 17.0 days (IQR, 12.5-18.0) in the long DVS group (p=0.040). The proportion of patients treated with corticosteroid therapy in the long DVS group was significantly higher than that in the short DVS group (41.9% versus 11.4%, p=0.005). Similarly, the number of patients admitted to the ICU in the long DVS group was also significantly higher than that in the short DVS group (16.1% versus 0%, p=0.045). Univariate regression analysis showed that disease severity, corticosteroid therapy, fever, and the time from onset to hospitalization were associated with a long DVS (Table 2 ). When the above variables were included in the multivariate logistic regression model, it was found that fever (temperature＞38.5℃) (OR 5.1, 95%CI: 1.5-18.1), corticosteroid therapy (OR 6.3, 95%CI：1.5-27.8), and the time from onset to hospitalization (OR 1.8, 95%CI: 1.19-2.7) were associated with increased odds of a long DVS (p＜0.05). We further analyzed the relationship between the maximum body temperature and DVS and found that DVS was gradually prolonged with increased maximum body temperature (Fig 2) . Maximum body temperature was divided into three groups: ＜37.3℃, 37.3-38.5 ℃, and ≥38.5℃, and the DVS in each group was shown to be 9 days (IQR, 7-11), Patients who were treated with corticosteroids were found to have a 6.3-fold increased risk of a long DVS, independent of their age, maximum body temperature, time from onset to hospitalization and disease severity ( Table 2) . The corticosteroid therapy effect may be dose-dependent and may vary according to the time of initiation; therefore, subgroup analysis of the following stratified groups was carried out: patients who received high-dose corticosteroid therapy (total dose of >300 mg methylprednisolone) and patients who received low-dose corticosteroid therapy (total dose of≤300 mg methylprednisolone). However, a statistically significant difference in the DVS between the two dose groups was not found (15.5 versus 16 days, p＞0.05) (Fig 3) . The detectability (percentage of patients) of SARS-CoV-2 RNA in patients treated with and without corticosteroids across time is depicted in Figure 1 . The median DVS in the corticosteroid treated and the untreated group was 16 days (IQR, 11.5-18.5 days) and 10 days (IQR, 8-13 days), respectively, (p=0.000). The cumulative proportion of patients with the undetectable virus at 6-8, 9-11, 12-14, 15-17 and 18-20 days from illness onset in the untreated group were 29.1%, 59.6%, 86.0%, 95.9%, and 98%, respectively, significantly higher than those in the corticosteroid treated group (Fig 4) . This article is protected by copyright. All rights reserved. This retrospective study describes the DVS in COVID-19 patients whose nucleic acid test was still negative after 2 weeks follow-up, and the median DVS in these patients was 11 days (IQR, 8-14. 3)( Table 1 ). In this study, the risk factors associated with prolonged DVS in adults who were hospitalized within 7 days of illness onset were investigated. It was found that severe/critical disease, corticosteroid therapy, fever, and shorter time from onset to hospitalization were associated with higher odds of a long DVS (Table 2) . Multivariate regression analysis showed that fever, corticosteroid therapy, and time from onset to hospitalization were independent risk factors for a long DVS in COVID-19 patients. Further analysis showed that the DVS was gradually prolonged with increased maximum body temperature (Fig 2) . Recently, a retrospective study of COVID-19 patients in Wuhan 4 showed that the median DVS was 20.0 days (IQR, 17.0-24. 0) in survivors, which was significantly longer than that in our patients, the reason for this result may be due to the heterogeneity of patients in the two studies. Outside Wuhan, the results of a study 5 from Beijing showed that the viral load in throat swabs and sputum of two COVID-19 patients peaked about 6 days after the onset of symptoms, and the virus could not be detected on the 9th and 12th day after onset, respectively. The results of this study are consistent with the DVS in patients included in our study. This article is protected by copyright. All rights reserved. A retrospective study 6 from Shanghai, China showed that the median time from the onset of symptoms to the first negative RT-PCR results for oropharyngeal swabs in convalescing patients was 9.5 (6.0-11.0) days. Another retrospective study 7 from Guangdong, China showed that the median DVS in 84 COVID-19 patients was 15 days, and the patients included in the study were not required to be hospitalized within 1 week after onset and followed up for 2 weeks. Thus, it can be seen that the DVS in COVID-19 patients in existing research results is quite different, and is considered to be related to the heterogeneity of the study population, and different medical conditions in the study area. At present, COVID-19 is spreading rapidly in many countries around the world. It is of great significance to understand the period of infection to control the pandemic. The present study found that the factors influencing the time of nucleic acid shedding were age, disease severity, the time from onset to hospitalization, maximum body temperature, and corticosteroid therapy. A recent study 7 on factors associated with prolonged viral RNA shedding in patients with showed that invasive mechanical ventilation was an independent risk factor for prolonged SARS-CoV-2 RNA shedding, which indirectly reflects the severity of illness and could affect nucleic acid clearance, which is consistent with our study findings. However, multivariate regression analysis did not identify disease severity as a factor influencing the DVS. This result may be attributed to the fact This article is protected by copyright. All rights reserved. that the patients in this study had mainly mild disease and the sample size was small. The results of this study suggested that the higher the COVID-19 patient's temperature, the longer the patient showed persistent positive nucleic acid. This result is consistent with a retrospective study 8 in children with COVID 19, which also showed that prolonged DVS in children with COVID-19 was associated with fever. We consider that the patient's temperature is related to the inflammatory response caused by the host immune response. However, cytokine levels in our patients were not determined; thus, the cause of prolonged viral clearance associated with high fever is unclear. The administration of corticosteroids in the treatment of viral pneumonia is controversial. Although, some western scholars 9 have suggested that there are no clinical data to indicate that a net benefit is derived from corticosteroids in the treatment of respiratory infection due to respiratory syncytial virus, influenza, However, Current studies 10, 11 have demonstrated that appropriate use of low-dose corticosteroids may have survival advantages in critically ill patients with COVID-19. On the other hand, many studies [12] [13] [14] [15] have shown that corticosteroid therapy can prolong the shedding time of SARS, MERS, and influenza virus, but there are few studies on COVID-19. In the present study, it was shown that This article is protected by copyright. All rights reserved. corticosteroid therapy can delay the shedding time of SARS-CoV-2 RNA, which was similar to another recent study on the shedding time of nucleic acid in patients with COVID-19 6 . In terms of the dose of corticosteroid therapy, we did not find a difference in the nucleic acid shedding time between the high dose and low dose groups (Fig 3) . A retrospective study 13 adjusted for baseline and time-varying confounders also found that early initiation of corticosteroid therapy, but not the dose, was associated with delayed MERS-CoV RNA clearance. But, in patients infected with H7N9 avian influenza, the detectable time of influenza virus nucleic acid in respiratory tract samples was prolonged when the daily dose of methylprednisolone was more than 150 mg 14 . Thus, the association between the dose and time of initiation of corticosteroid therapy and the DVS in COVID-19 patients requires further study. Also, the DVS was strongly related to the host immune status in immunocompromised patients with influenza A. In immunocompromised patients, the shedding time of influenza A virus was prolonged 16 , and it was speculated that corticosteroid therapy will affect the immune status of patients, and then affect the virus shedding time. Our study has some limitations. First, there may be a certain bias in the results of this study as the sample size was small and the number of critically ill patients was low. Second, we only analyzed nucleic acid in throat swabs, and not in blood, sputum, feces, or anal swabs. However, it has been reported 17,18 that the duration Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients Factors associated with prolonged viral RNA shedding in patients with COVID-19 Symptomatic Infection is Associated with Prolonged Duration of Viral Shedding in Mild Coronavirus Disease 2019: A Retrospective Study of 110 Children in Wuhan Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Effects of early corticosteroid treatment on plasma SARSassociated Coronavirus RNA concentrations in adult patients Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome Adjuvant Corticosteroid Treatment in Adults With Influenza A (H7N9) Viral Pneumonia The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study Creatine kinase, U/L 70